Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Akorn (AKRX) Gets FDA Warning Letter for Illinois Facility

by Zacks Equity Research

Akorn, Inc. (AKRX) suffers a setback with the FDA handing over a warning letter post an inspection of its Illinois manufacturing facility in April and May of 2018.

INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data

by Zacks Equity Research

INSYS Therapeutics' (INSY) epinephrine nasal spray demonstrates pharmacokinetic profile similar to two reference products EpiPen and Adrenalin in treating patients with anaphylaxis, a life-threatening allergic reaction.

Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect

by Zacks Equity Research

Acorda (ACOR) aims to unveil its newly FDA-approved Parkinson's disease drug, Inbrija, in the first quarter of 2019. The company's pipeline looks strong.

MYL vs. SUPN: Which Stock Is the Better Value Option?

by Zacks Equity Research

MYL vs. SUPN: Which Stock Is the Better Value Option?

Is Mylan (MYL) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ironwood/Allergan Settle Linzess Patent Litigation With Mylan

by Zacks Equity Research

Ironwood (IRWD) and Allergan announce agreement with Mylan to resolve patent litigation, granting Mylan license to launch a generic version of Linzess in the United States not earlier than Feb 5, 2030.

Generic Industry on Path to Recovery: 3 Hot Picks for 2019

by Zacks Equity Research

The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.

Will AbbVie (ABBV) Shares Regain Lost Momentum in 2019?

by Zacks Equity Research

Though AbbVie's (ABBV) stock was down this year, it looks well poised for a recovery in 2019.

Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija

by Zacks Equity Research

Acorda (ACOR) gains an FDA nod for its lead Parkinson's drug Inbrija pertaining to the treatment of OFF periods in patients afflicted with the disease.

Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus

by Zacks Equity Research

Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.

Teva (TEVA) Stock Poised to Record Big Gains in 2019?

by Zacks Equity Research

Teva's (TEVA) shares outperform the industry in 2018 so far after a massive drop in 2017. Let's see how it is poised for the next year.

Generic Drugmakers Down on Allegations of Price Fixing

by Zacks Equity Research

An article in The Washington Post levels charges of price fixing against several generic drugmakers, driving their shares down.

Mylan (MYL) Down 9.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mylan Expands Recall of Valsartan to All Unexpired Lots

by Zacks Equity Research

Mylan (MYL) expands recall of batches of blood pressure medicine in the United States to include all Valsartan-based products within expiry.

AbbVie Settles With Pfizer for Humira Biosimilar in U.S.

by Zacks Equity Research

AbbVie (ABBV) strikes a deal with Pfizer to launch its biosimilar of Humira in the United States in November

Theravance Pipeline Strong, Plans Yupelri Launch by Year End

by Zacks Equity Research

Theravance (TBPH) plans to launch its newly approved COPD drug, Yupelri, before the end of 2018. However, sole dependence on Yupelri for revenues is a concern.

Teva (TEVA) Launches First Generic Version of Mylan's EpiPen

by Zacks Equity Research

Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.

3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far

by Zacks Equity Research

Glaxo's (GSK) shares have outperformed the industry this year. Here are some reasons for the same.

J&J Loses Appeal to Halt Generic Zytiga Launch, Stock Down

by Zacks Equity Research

A U.S. appeals court declines J&J's (JNJ) request to prevent the launch of generic versions of Zytiga. Stock down more than 3%.

Mylan Recalls Valsartan Lots, Gets FDA Warning for Facility

by Zacks Equity Research

Mylan (MYL) recalls batches of blood pressure medicine in the United States. The company receives warning letter from the FDA for the manufacturing facility in Morgantown, WV.

J&J Gets Positive CHMP Opinion for Prostate Cancer Treatment

by Zacks Equity Research

Johnson & Johnson's (J&J) apalutamide gets positive CHMP opinion for the treatment of adult patients with non-metastatic castration-resistant prostate cancer.

Acorda Down More Than 30% in the Past 3 Months: Here's Why

by Zacks Equity Research

Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States while its lead Parkinson disease candidate Inbrija's review timeline gets extended by three months.

Momenta (MNTA) Reports Narrower-Than-Expected Loss in Q3

by Zacks Equity Research

Momenta (MNTA) posts narrower-than-expected loss in the third quarter, while revenues fall short of estimates.

    Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ

    by Zacks Equity Research

    Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.

    Company News For Nov 7, 2018

    by Zacks Equity Research

    Companies In The News Are: ELF,ABC,MNK,MYL